Status:
UNKNOWN
Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina
Lead Sponsor:
Second Xiangya Hospital of Central South University
Conditions:
Microvascular Angina
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This study is undertaken to determine if ticagrelor augments adenosine-induced coronary flow reserve (CFR), ameliorates clinical symptomatology and exercise tolerance in patients with MVA
Detailed Description
Considering the reduced CFR and increased platelet aggregability in patients with MVA, together with the augmented effect on adenosine-mediated coronary blood flow and potent antiplatelet effect of ti...
Eligibility Criteria
Inclusion
- For inclusion in the study subjects should fulfill the following criteria:
- Provision of informed consent prior to any study specific procedures
- Female or male aged 18-80 years
- A diagnosis of stable primary MVA based on the presence of
- a history of typical effort angina,
- exercise-induced ST-segment depression\>1 mm,
- normal or near-normal (coronary artery stenosis\<50%) coronary angiography,
- absence vasospastic angina
- a coronary flow reserve (CFR) \<2.5 in the left anterior descending coronary artery as assessed by coronary blood flow (CBF) response to adenosine at transthoracic Doppler echocardiography
- suboptimal control of symptoms on conventional anti-ischemic therapy, as indicated by the occurrence of \>1 episode per week of angina
Exclusion
- ubjects should not enter the study if any of the following exclusion criteria are fulfilled:
- concomitance with any of the cardiac condition below
- significant （\>50%）coronary plaque disease
- coronary artery spasm at angiography or other evidence of vasospastic angina
- valvular or other structural heart disease
- uncontrolled hypertension
- abnormal echocardiographic examination including left ventricular hypertrophy
- no previous consumption of the ticagrelor
- no apparent contraindications to ticagrelor administration.
- History of Intracranial Hemorrhage
- Active Bleeding
- Severe Hepatic Impairment: AST and ALT are greater than 3 times of the upper limit. Bilirubin is greater than the upper limit.
- hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product
- severe COPD or asthma
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2017
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT02284048
Start Date
November 1 2014
End Date
November 1 2017
Last Update
November 6 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.